HOCHDORF Holding AG

EQS-Adhoc: HOCHDORF Holding AG: Shareholding brings HOCHDORF closer to the end user


EQS Group-Ad-hoc: HOCHDORF Holding AG / Key word(s): Investment
HOCHDORF Holding AG: Shareholding brings HOCHDORF closer to the end user

20-Dec-2016 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
--------------------------------------------------------------------------------
HOCHDORF Group Press Release: Shareholding brings HOCHDORF closer to the end
user

Closing of the majority shareholding for Pharmalys

Hochdorf, 20 December 2016 -With all pre-conditions met, the closing for the
majority holding in Pharmalys Laboratories SA and in the jointly-founded
Pharmalys Africa Sarl has been completed. HOCHDORF currently has a 49% holding
in Pharmalys Tunisia SA. This means that the integration of these companies into
the HOCHDORF Group can be completed by the end of 2016.

With all conditions met, the closing of the HOCHDORF Group's shareholdings in
the Pharmalys Group companies has been completed today (Monday). This means that
HOCHDORF assumes a 51% majority holding in Pharmalys Laboratories SA and in the
jointly-founded Pharmalys Africa Sarl effective at the end of 2016. Only 49% of
the shares are being acquired in Pharmalys Tunisia SA in a first step. The
expectation is that the shareholding will likewise increase to 51% once the
takeover procedure has been approved.

Forward integration strategy
The holding in Pharmalys is an important milestone towards meeting the Group's
strategic objectives for 2020. By then HOCHDORF Group aims to develop into a
globally active, profitable niche-market company with premium products.
"HOCHDORF aims to move closer towards the end user and this majority holding in
Pharmalys is an important step in this direction," says Thomas Eisenring, CEO of
the HOCHDORF Group. Pharmalys is active in over 40 countries in the Middle East,
Africa and Asia. HOCHDORF has been producing infant formula for Pharmalys since
2008.

On 29 November 2016, HOCHDORF Holding Ltd shareholders voted for a capital
increase that was necessary for the majority shareholding as well as an increase
to the transferability restrictions from 5% to 15%. Additional details relating
to the Pharmalys transaction are available on the HOCHDORF Group
website:www.hochdorf.com.

Contact:
Christoph Hug, Head of Corporate Communications, HOCHDORF Group.
Tel: +41 (0)41 914 65 62 / +41 (0)79 859 19 23,christoph.hug@hochdorf.com

Additional features:


Document:http://n.eqs.com/c/fncls.ssp?u=MNEWDVEQKD
Document title: Closing HOCHDORF - Pharmalys
--------------------------------------------------------------------------------
End of ad hoc announcement------------------------------------------------------
--------------------------Information and Explanation of the Issuer to this
News:


In 2015 the HOCHDORF Group, which is headquartered in Hochdorf, generated a
consolidated gross sales revenue of CHF 551.2 million. It is one of the leading
foodstuff companies in Switzerland, with more than 625 employees as at 31
December 2015. Made from such natural ingredients as milk, wheat germ, and
oilseeds, HOCHDORF products have been contributing to the health and well-being
of the young and old alike since 1895. Our customers include the food industry
and wholesalers and retailers. Our products are sold in more than 90 countries.
HOCHDORF stock is traded on the SIX Swiss Exchange in Zurich (ISIN
CH0024666528).

--------------------------------------------------------------------------------

Language: English

Company:  HOCHDORF Holding AG

          Siedereistrasse 9

          6281 Hochdorf

          Switzerland

Phone:    +41 41 914 65 65

Fax:      +41 41 914 66 66

E-mail:hochdorf@hochdorf.com

Internet: www.hochdorf.com

ISIN:     CH0024666528

Listed:   SIX Swiss Exchange



 

End of Announcement EQS Group News Service

--------------------------------------------------------------------------------

531549  20-Dec-2016 CET/CEST
 



Weitere Meldungen: HOCHDORF Holding AG

Das könnte Sie auch interessieren: